C. Phelps

发表

Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies

J. Machiels, L. Dirix, Sunil Sharma, 2014, Cancer Chemotherapy and Pharmacology.

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

M. Hallek, A. Chanan-Khan, A. Howes, 2016, The Lancet. Oncology.

A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

J. Camm, R. Plummer, R. Cowan, 2013, Clinical Cancer Research.

Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome

M. Weichenthal, R. Cowan, M. Beylot-Barry, 2016, The British journal of dermatology.

Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma

P. Moreau, X. Leleu, C. Touzeau, 2016, Leukemia & lymphoma.

Sequence variants in patients with primary and acquired resistance to Ibrutinib in the phase 3 MCL3001 (RAY) trial

G. Lenz, J. Goldberg, M. Dreyling, 2016 .

First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial

J. Hainsworth, H. Burris, D. Yardley, 2004 .

First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial.

J. Hainsworth, H. Burris, D. Yardley, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

M. Hallek, A. Chanan-Khan, A. Howes, 2018, Leukemia.

Phase I/IIa, randomized, open-label, drug-drug interaction study of trabectedin and rifampin in patients with advanced cancer.

Sunil Sharma, R. Knoblauch, T. Parekh, 2013 .

Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.

A. Chanan-Khan, A. Howes, G. Fraser, 2016 .

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

J. Byrd, U. Jaeger, T. Kipps, 2016 .

Early Changes in Circulating T-Cell Immune Profiles in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from the Phase 3, Double-Blind HELIOS Trial

A. Chanan-Khan, D. B. Yehuda, A. Howes, 2016 .

Phase 1b Dose Escalation Study Of Oral Quisinostat, a Histone Deacetylase Inhibitor (HDACi), In Combination With Velcade (Bortezomib) and Dexamethasone For Patients With Relapsed Multiple Myeloma (MM)

X. Leleu, C. Touzeau, T. Facon, 2013 .

IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY

M. Hallek, A. Howes, G. Fraser, 2016 .

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

M. Hallek, A. Chanan-Khan, A. Howes, 2016, The Lancet. Oncology.

Phase Ib dose escalation study of oral quisinostat, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma.

P. Moreau, X. Leleu, C. Touzeau, 2013 .